Iba Particle Therapy India Profile
Key Indicators
- Authorised Capital ₹ 5.20 M
- Paid Up Capital ₹ 5.00 M
- Company Age 11 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 1.06%
- Profit Growth 39.45%
- Ebitda 36.92%
- Net Worth 45.48%
- Total Assets 35.46%
About Iba Particle Therapy India
Iba Particle Therapy India Private Limited (IPTIPL) is a leading Private Limited Foreign Company Incorporated In India incorporated in India on 31 December 2013 and has a history of 11 years and one month. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.20 M and a paid-up capital of Rs 5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Olivier Legrain, Soumya Chandramouli, and Rakeshkumar Pathak serve as directors at the Company.
Company Details
-
Location
Chennai, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U74900TN2013FTC094391
-
Company No.
094391
-
Company Classification
Private Limited Foreign Company Incorporated In India
-
Incorporation Date
31 Dec 2013
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Iba Particle Therapy India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Olivier Legrain
|
Director | 31-Dec-2013 | Current |
Soumya Chandramouli
|
Director | 13-Feb-2018 | Current |
|
Rakeshkumar Pathak
|
Director | 04-Jul-2017 | Current |
Financial Performance of Iba Particle Therapy India.
Iba Particle Therapy India Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 1.06% increase. The company also saw a substantial improvement in profitability, with a 39.45% increase in profit. The company's net worth Soared by an impressive increase of 45.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Iba Particle Therapy India?
In 2023, Iba Particle Therapy India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
International Business Excellence & Advi Sory Services LlpRakeshkumar Pathak is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Iba Particle Therapy India?
Iba Particle Therapy India has a workforce of 31 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Iba Particle Therapy India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Iba Particle Therapy India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
